Plain-English translation of NCT07009327 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing photodynamic therapy — a treatment that uses a special light-sensitive medication combined with red light — to treat a precancerous condition of the cervix called CIN3. Doctors want to understand how well and how safely this treatment works in real-world settings for women who need it.
CIN3 is a precancerous condition that can progress to cervical cancer if not treated, but current treatment options may have limitations. This study aims to see if the new light-based approach could be an effective and safe alternative for women with this condition.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would receive the light-based treatment as your chosen therapy for CIN3. The treatment involves applying a light-sensitive medication to the cervical area and then exposing it to red light. Your doctors will monitor you to see how well the treatment works and track any side effects over time.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China
Peking University Third Hospital
Enrollment target
~100 participants
Started
January 2024
Primary completion
December 2028
Age range
18 Years – 65 Years
Sex
Female only
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qin Han
Peking Unniversity Third Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.